ATE240314T1 - Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung - Google Patents

Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung

Info

Publication number
ATE240314T1
ATE240314T1 AT97912445T AT97912445T ATE240314T1 AT E240314 T1 ATE240314 T1 AT E240314T1 AT 97912445 T AT97912445 T AT 97912445T AT 97912445 T AT97912445 T AT 97912445T AT E240314 T1 ATE240314 T1 AT E240314T1
Authority
AT
Austria
Prior art keywords
substituted
optionally
crystals
production
benzimidazole derivatives
Prior art date
Application number
AT97912445T
Other languages
English (en)
Inventor
Masayasu Kato
Toru Ishida
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17920069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE240314(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE240314T1 publication Critical patent/ATE240314T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT97912445T 1996-11-14 1997-11-13 Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung ATE240314T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30336196 1996-11-14
PCT/JP1997/004136 WO1998021201A1 (en) 1996-11-14 1997-11-13 Crystals of benzimidazole derivatives and their production

Publications (1)

Publication Number Publication Date
ATE240314T1 true ATE240314T1 (de) 2003-05-15

Family

ID=17920069

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97912445T ATE240314T1 (de) 1996-11-14 1997-11-13 Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung

Country Status (18)

Country Link
US (1) US6002011A (de)
EP (1) EP0944617B1 (de)
KR (1) KR100519576B1 (de)
CN (2) CN1171885C (de)
AT (1) ATE240314T1 (de)
AU (1) AU731776B2 (de)
CA (1) CA2269053C (de)
DE (1) DE69722027T2 (de)
DK (1) DK0944617T3 (de)
ES (1) ES2199356T3 (de)
ID (1) ID21547A (de)
IL (1) IL129724A (de)
NZ (1) NZ335145A (de)
PT (1) PT944617E (de)
TR (1) TR199901055T2 (de)
TW (1) TW385306B (de)
WO (1) WO1998021201A1 (de)
ZA (1) ZA9710255B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
JP3926936B2 (ja) * 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
ATE314854T1 (de) * 1999-02-04 2006-02-15 Joern Bullerdiek Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs
US7110444B1 (en) 1999-08-04 2006-09-19 Parkervision, Inc. Wireless local area network (WLAN) using universal frequency translation technology including multi-phase embodiments and circuit implementations
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
PL333847A1 (en) * 1999-06-18 2001-01-02 Inst Farmaceutyczny Crystalline forms of lansoprozole and method of obtaining lansoprazole in pharmacologically advanthageous crystalline form
ATE298334T1 (de) 1999-06-30 2005-07-15 Takeda Pharmaceutical Kristalle von lansoprazole
DE60131649T2 (de) 2000-05-15 2008-10-30 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung eines kristalls
JP5412023B2 (ja) * 2000-08-04 2014-02-12 武田薬品工業株式会社 ベンズイミダゾール化合物の塩およびその用途
EP1310252A4 (de) 2000-08-18 2009-06-10 Takeda Pharmaceutical Injektionen
KR20100002278A (ko) 2000-12-01 2010-01-06 다케다 야쿠힌 고교 가부시키가이샤 (ｒ)- 또는 (ｓ)-란소프라졸의 결정
DE10140492A1 (de) 2001-08-17 2003-08-14 Gruenenthal Gmbh Hydrate von gegebenenfalls substituierten 2-(2-Pyridinyl)methylthio-1H-benzimidazolen und Verfahren zu ihrer Herstellung
ES2426723T3 (es) 2001-10-17 2013-10-24 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
HRP20040767A2 (en) * 2002-02-19 2004-12-31 Teva Pharma Desolvating solvates of atorvastatin hemi-calcium
KR20040093187A (ko) * 2002-03-27 2004-11-04 테바 파마슈티컬 인더스트리즈 리미티드 란소프라졸 다형 및 그것의 제조 방법
KR100873419B1 (ko) * 2002-06-18 2008-12-11 페어차일드코리아반도체 주식회사 높은 항복 전압, 낮은 온 저항 및 작은 스위칭 손실을갖는 전력용 반도체 소자
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
US6909004B2 (en) * 2002-08-21 2005-06-21 Teva Pharmaceutical Industries Ltd. Method for the purification of lansoprazole
EP1764364A1 (de) * 2002-08-21 2007-03-21 Teva Pharmaceutical Industries Ltd Eine Methode zur Reinigung von Lansoprazol
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004035052A1 (ja) 2002-10-16 2004-04-29 Takeda Pharmaceutical Company Limited 安定な固形製剤
EP1465890B1 (de) * 2002-11-18 2007-04-04 Teva Pharmaceutical Industries Ltd. Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol
EP1743893A1 (de) 2002-11-18 2007-01-17 Teva Pharmaceutical Industries Ltd. Stabiles Lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm Wasser und mehr als 200 ppm bis zu 5000 ppm Alkohol
EP1485373A1 (de) * 2003-02-05 2004-12-15 Teva Pharmaceutical Industries Limited Verfahren zur stabilisierung von lansoprazol
US7005732B2 (en) * 2003-10-21 2006-02-28 Honeywell International Inc. Methods and systems for providing MEMS devices with a top cap and upper sense plate
TW200526268A (en) * 2003-12-17 2005-08-16 Takeda Pharmaceutical Injectable composition
SE0400410D0 (sv) * 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
CA2787378C (en) * 2004-09-13 2015-11-03 Takeda Pharmaceutical Company Limited Method for producing lansoprazole crystal
EP1681056A1 (de) 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Verfahren zur Herstellung von Lansoprazol
US8871273B2 (en) 2005-02-25 2014-10-28 Takeda Pharmaceutical Company Limited Method for producing granules
US20090030044A1 (en) * 2005-06-07 2009-01-29 Takeda Pharmaceutical Company Limited Crystal of Salt of Benzimidazole Compound
CA2611917A1 (en) * 2005-06-13 2006-12-21 Takeda Pharmaceutical Company Limited Injection
RU2496480C2 (ru) 2005-12-28 2013-10-27 Такеда Фармасьютикал Компани Лимитед Твердый препарат с контролируемым высвобождением
KR100758600B1 (ko) * 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US8129536B2 (en) * 2006-09-22 2012-03-06 Orchid Chemicals & Pharmaceuticals Limited Method for the purification of lansoprazole
WO2008068767A2 (en) * 2006-12-07 2008-06-12 Hetero Drugs Limited A novel crystalline form of lansoprazole
ITMI20062481A1 (it) * 2006-12-22 2008-06-23 Recordati Chem Pharm Processo per la preparazione di lansoprazolo forma i microcristallino
EP2098250B1 (de) 2006-12-28 2016-09-28 Takeda Pharmaceutical Company Limited Oral zerfallende feste zubereitung
JP2011507977A (ja) * 2007-12-31 2011-03-10 武田薬品工業株式会社 （ｒ）−２−［［［３−メチル−４−（２，２，２−トリフルオロエトキシ）−２−ピリジニル］メチル］スルフィニル］−１ｈ−ベンズイミダゾールの溶媒和物結晶形
EA017064B1 (ru) * 2008-03-10 2012-09-28 Такеда Фармасьютикал Компани Лимитед Кристаллическое производное бензимидазола
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
US20130012714A1 (en) * 2010-02-11 2013-01-10 Orchid Chemicals & Pharmaceuticals Limited Novel solvate of dexlansoprazole
BR112013013571A2 (pt) 2010-12-03 2016-10-11 Takeda Pharmaceutical comprimido para a desintegração oral
MX2013007588A (es) 2010-12-27 2013-08-09 Takeda Pharmaceutical Comprimido de desintegracion oral.
CN102180866B (zh) * 2011-05-23 2013-03-13 中山大学 兰索拉唑晶型及其制备方法和应用
CN103012369B (zh) * 2011-05-23 2014-04-23 中山大学 兰索拉唑n晶型及其制备方法和应用
JP5925318B2 (ja) 2011-11-30 2016-05-25 武田薬品工業株式会社 有核錠
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
JP6364406B2 (ja) 2013-05-21 2018-07-25 武田薬品工業株式会社 口腔内崩壊錠
CN103539728A (zh) * 2013-10-14 2014-01-29 安徽国星生物化学有限公司 一种拉唑类药物中间体氯甲基吡啶衍生物的合成方法
CN103539729A (zh) * 2013-10-14 2014-01-29 安徽国星生物化学有限公司 一种氯甲基吡啶衍生物的工业化生产方法
CN104829594A (zh) * 2015-05-15 2015-08-12 苗怡文 一种治疗胃溃疡的药物兰索拉唑化合物
CN104817492B (zh) * 2015-05-22 2018-05-18 抚州三和医药化工有限公司 兰索拉唑中间体2-羟甲基-3-甲基-4-(2,2,2-三氟乙氧基）吡啶的分离纯化方法
KR102649498B1 (ko) 2023-12-06 2024-03-20 거산해운(주) 선사별 실시간 통합 예약 정보를 기반으로 한 화주의 해상 운송 예약 자동화 플랫폼 서비스 제공 방법, 장치 및 시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4018642C2 (de) * 1990-06-11 1993-11-25 Byk Gulden Lomberg Chem Fab Neue Salzform des 5-Difluormethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]-1H-benzimitazol-Natriumsalzes
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5374730A (en) * 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives

Also Published As

Publication number Publication date
ID21547A (id) 1999-06-24
TW385306B (en) 2000-03-21
AU4965297A (en) 1998-06-03
CN1616457A (zh) 2005-05-18
WO1998021201A1 (en) 1998-05-22
ZA9710255B (en) 1999-05-13
IL129724A0 (en) 2000-02-29
CA2269053C (en) 2006-07-18
AU731776B2 (en) 2001-04-05
PT944617E (pt) 2003-08-29
DE69722027D1 (de) 2003-06-18
DK0944617T3 (da) 2003-09-01
ES2199356T3 (es) 2004-02-16
EP0944617B1 (de) 2003-05-14
CA2269053A1 (en) 1998-05-22
IL129724A (en) 2004-02-19
DE69722027T2 (de) 2004-03-25
TR199901055T2 (xx) 1999-07-21
KR100519576B1 (ko) 2005-10-07
CN100355749C (zh) 2007-12-19
EP0944617A1 (de) 1999-09-29
NZ335145A (en) 2000-12-22
KR20000053158A (ko) 2000-08-25
HK1020194A1 (en) 2000-03-31
CN1171885C (zh) 2004-10-20
CN1237167A (zh) 1999-12-01
US6002011A (en) 1999-12-14

Similar Documents

Publication Publication Date Title
ATE240314T1 (de) Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung
HUP9802859A2 (hu) Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként
DE69534975D1 (de) Verwendung von noribogain derivaten zur behandlung von chemischer abhängigkeit bei säugern
DE3675087D1 (de) Pyridoncarbonsauere-derivate und verfahren zu ihrer herstellung.
ATE46164T1 (de) 1,4:3,6-dianhydro-hexit-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
IE872588L (en) Compounds
AT380471B (de) Verfahren zur herstellung von neuen 2-oxoazetidin-derivate
KR850003719A (ko) 시아노피라졸 제초제에 대한 개량
DE3785878D1 (de) 3,4-disubstituierte-2-azetidinon-derivate und verfahren zu ihrer herstellung.
ATE75737T1 (de) Indenothiazolderivate und verfahren zu ihrer herstellung.
ATE239701T1 (de) Polyethoxylierte retinamid-derivate und verfahren zu ihrer herstellung
DE3864707D1 (de) Benzoxazin-derivate und verfahren zu ihrer herstellung.
ATE234818T1 (de) Chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
HUP0100453A1 (hu) Eljárás izokarbamidok előállítására
DE69614841D1 (de) Verfahren zur Herstellung von Galanthaminderivate durch asymmetrische Reduktion
ATE137747T1 (de) Aminobenzolverbindungen, herstellung und verwendung
ES2016017A6 (es) Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico.
ATE20063T1 (de) 3-pyridyl-5-alkoxy(oder phenoxy- oder aralkyloxy- )pyrazol-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ES407816A1 (es) Metodo para producir derivados de benzodiazepina.
ATE195115T1 (de) Verfahren zur herstellung von 5,6-dihydroxy-2- amino-1,2,3,4-tetrahydronaphthalin-derivaten
PT99280A (pt) Processo de preparacao de derivados do indolo e de composicoes farmaceuticas
DE3777464D1 (de) Fluorine enthaltende vitamin-d3-derivate und verfahren zu ihrer herstellung.
DE68907857D1 (de) Beta-d-phenylthioxyloside, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
HUP0003024A2 (hu) Eljárás nitro-guanidin-származékok előállítására és az új kiindulási vegyületek
DE3772852D1 (de) Thiadiazolylacetamid-derivate, verfahren zu ihrer herstellung und ihre verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0944617

Country of ref document: EP